Prevalence, incidence, and clinical relevance of the reverse transcriptase V207I mutation outside the YMDD motif of the hepatitis B virus polymerase during lamivudine therapy

B Zöllner; M Sterneck; K Wursthorn; J Petersen; M Schröter; R Laufs; H-H Feucht

doi:10.1128/JCM.43.5.2503-2505.2005

Prevalence, incidence, and clinical relevance of the reverse transcriptase V207I mutation outside the YMDD motif of the hepatitis B virus polymerase during lamivudine therapy

J Clin Microbiol. 2005 May;43(5):2503-5. doi: 10.1128/JCM.43.5.2503-2505.2005.

Authors

B Zöllner¹, M Sterneck, K Wursthorn, J Petersen, M Schröter, R Laufs, H-H Feucht

Affiliation

¹ Institute for Infectious Diseases, University Hospital Hamburg-Eppendorf, Martinistr. 52, D-20246 Hamburg, Germany. [email protected]

Abstract

The reverse transcriptase V207I mutation within the hepatitis B virus (HBV) polymerase is associated with resistance to lamivudine in vitro. The prevalence of this mutation in treatment-naive patients was 1% (1/96). A follow-up of the patient carrying this mutation prior to treatment revealed no loss of sensitivity of HBV to lamivudine in vivo.

Publication types

Case Reports

MeSH terms

Amino Acid Sequence
Amino Acid Substitution*
Antiviral Agents / therapeutic use
DNA, Viral / blood
Drug Resistance, Viral
Hepatitis B / drug therapy*
Hepatitis B virus / drug effects
Hepatitis B virus / enzymology
Hepatitis B virus / genetics*
Humans
Interferon alpha-2
Interferon-alpha / therapeutic use
Lamivudine / therapeutic use*
Polyethylene Glycols / therapeutic use
RNA-Directed DNA Polymerase / genetics*
Recombinant Proteins

Substances

Antiviral Agents
DNA, Viral
Interferon alpha-2
Interferon-alpha
Recombinant Proteins
Lamivudine
Polyethylene Glycols
RNA-Directed DNA Polymerase
peginterferon alfa-2a